Novocure (NVCR) announced that Japan’s Ministry of Health, Labour and Welfare approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer who have progressed on or after platinum-based chemotherapy.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Novocure announces coverage for Tumor Treating Fields therapy in Spain
- Novocure submits Tumor Treating Fields therapy premarket approval application
- NovoCure’s Pivotal Study on Optune® for Glioblastoma: A Market Game-Changer?
- Novocure’s Earnings Call: Clinical Successes & Cautious Optimism
- Positive Outlook for NovoCure: Strong Financial Performance and Promising Pipeline Developments